Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 4:15 PM EDT | Source: Phio Pharmaceuticals Corp.Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL® siRNA ...